Discover Great Companies Discover Great Clients
Popularity  20.9万   |   Followers  225   |   Likes  39   |   Feedback  155 Claim this company

A pharmaceutical group committed to the research, development, product

No.23 Chengdu City Popularity Ranking No.2 Jinniu District No.30 Sichuan Pr No.1 Healthcare Supplies No.1 Medical Devices No.1 Medical Products No.1 Medical Devices R&D No.2 Yi Yao Ji Group No.2 Kang Zhong Liu Yao No.3 Xin Xue Guan Yao No.3 Chinese Patent Medicines No.3 Pharmaceutical R&D No.3 Zhu She Liquids No.4 Xin Yao R&D No.4 Chemistry Pharmaceuticals 博士后工作站 高新技术企业 企业技术中心 驰名商标 创新型企业 副会长单位 ISO9001认证
More

Company Overview

  • Nature: Listed Company Size: 1000-4999 employees Founded: 30年
  • Industry: Pharmaceutical/Bioengineering
  • Full name: Chengdu Kanghong Pharmaceutical Group Joint-stock Co., Ltd.。

Development Stage

  • Stage: IPO上市, 主板, 深交所。
  • Ranking: Ranked #23 in Chengdu City by popularity Ranked #1 in Chengdu Healthcare Supplies Company by popularity Ranked #1 in Chengdu Medical Devices Company by popularity Ranked #1 in Chengdu Medical Products Company by popularity Ranked #1 in Chengdu Medical Devices R&D Company by popularity
  • Honors: 2025中国新经济500强 2022中国企业慈善公益500强 博士后工作站 高新技术企业 According to algorithm
  • News: 2026-03-26:康弘药业:注射用KHN922药物临床试验获批。
  • Salary: 47.5% of positions earn 10-20K, In 2026 vs last yeargrew by 2%.。Master's salary: ¥32.4K, Doctorate salary: ¥32.6K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 55.4%, "Computer/Network/Technology": 29.7%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 19.8%。
  • Recruiting: In 2026 vs 2025grew by 97%. Demand for highly educated talent: Master's: 105, Doctorate: 60.
  • Requirement: Education: 本科 leads with 41.8%. Experience: 1-3年 leads with 39.3%.
  • Region: Distributed across 54 regions, 成都: 44.5%, 北京: 7.1%, 上海: 4.2%, 广州: 3.1%.

About the Company

[Summary] A pharmaceutical group committed to the research, development, product

Chengdu Kanghong Pharmaceutical Group Joint-stock Co., Ltd. (hereinafter referred to as "Kanghong Pharmaceutical", stock code: 002773) is a pharmaceutical group dedicated to the research, development, production, sales, and after-sales service of biological products, traditional Chinese medicines, and chemical drugs, including 7 subsidiaries such as Kanghong Biologics, Kanghong Pharmaceutical, and Jishengtang. Kanghong Pharmaceutical has always adhered to the core development strategy of professionalism, innovation, and internationalization, possessing a corporate technology center, a postdoctoral research workstation, and a key laboratory of Sichuan Province, and has established multiple innovation platforms related to biological products, chemical drugs, and traditional Chinese medicines. Currently, Kanghong Pharmaceutical lays out its products based on the clinical needs of core therapeutic areas, with main products covering core therapeutic areas including ophthalmology, central nervous system, digestive system, and others. Currently, it holds more than 120 invention patents (over 40 foreign patents) and has undertaken one National Key Basic Research and Development Program (973 Plan), three National High-Tech Research and Development Programs (863 Plan), three National "Major New Drug Creation" Science and Technology Major Projects and other special projects, as well as over 30 science and technology key projects in Sichuan Province and Chengdu.
Kanghong Pharmaceutical adheres to the development strategy of combining professionalism and innovation, focusing on the research and development of innovative products, achieving a sustainable development strategy of "producing one generation, reserving one generation, and developing one generation." Currently, Kanghong Pharmaceutical has 12 main products in production and 10 main products under research. Among them, Kanghong's independently developed China-original Class 1 biological new drug Conbercept ophthalmic injection (trade name: Lumitin) obtained the new drug certificate and drug registration approval from the National Food and Drug Administration in November 2013, and was launched in March 2014, filling the market gap for domestic treatment of macular degeneration and breaking the monopoly of imported drugs in this field in the Chinese market, providing many Chinese patients facing blindness with better and more economical treatment opportunities. Facing the fierce competition pattern of innovative drugs, Kanghong actively explores professional academic dissemination of this product at home and abroad, builds professional and innovative academic competitiveness, shapes an international national brand, and lays a good foundation for Chinese drugs to enter the international market and for the world to know Kanghong and accept Lumitin.
Since its establishment, Kanghong Pharmaceutical has received care and guidance from governments at all levels and widespread attention from all sectors of society: in 2012, it was listed by the Ministry of Science and Technology, the State-owned Assets Supervision and Administration Commission of the State Council, and the All-China Federation of Trade Unions as one of the fifth batch of national "Innovative Pilot Enterprises"; in 2013, it was rated as an "Excellent Private Enterprise" by the Sichuan Provincial People's Government; in 2014, it was rated as one of the "Top 100 Chinese Pharmaceutical Manufacturing Enterprises" by the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce.
Kanghong Pharmaceutical will, as always, uphold the corporate purpose of "prosperous era and helping all beings," adhere to the professional and innovative development path, continue to develop high-quality, high-tech pharmaceutical products, serve public health, promote industrial progress, and repay social care.
Company homepage:

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Kanghong Pharmaceutical Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market: 主板
  • Deal: 深交所

Kanghong Pharmaceutical How Fast Is Hiring Growing? (584 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 113%
  • 2024: Up 103%
  • 2023: Up 23%
  • 2022: Down 40%
Kanghong Pharmaceutical Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Kanghong Pharmaceutical Campus Recruitment & Advanced Degree Talent Demand
Graduates 172 Interns 4 Master's 105 Doctorate 60
Note: How fast is hiring at Chengdu Kanghong Pharmaceutical Group Joint-stock Co., Ltd. growing? Kanghong Pharmaceutical2026: 1901 openings (up 97%), 2025: 963 openings (up 113%), 2024: 453 openings (up 103%), 2023: 223 openings (up 23%), 2022: 182 openings (down 40%), 2021: 304 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Kanghong Pharmaceutical Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 122%
  • 2024: Up 194%
  • 2023: Down 35%
  • 2022: Up 44%
Kanghong Pharmaceutical Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Chengdu Kanghong Pharmaceutical Group Joint-stock Co., Ltd. growing? Kanghong PharmaceuticalMaster's recruitment over the years: 2025: 111 openings (up 122%), 2024: 50 openings (up 194%), 2023: 17 openings (down 35%), 2022: 26 openings (up 44%), 2021: 18 openings. Kanghong Pharmaceutical master talent ranking in Chengdu: #2, Kanghong Pharmaceutical master salary mostly around 20-50K and above.

Kanghong Pharmaceutical Doctoral Degree Job Demand Analysis

(More)
+175%
Growth Rate
2026 vs 2025
  • 2025: Up 191%
  • 2024: Down 15%
  • 2023: Down 7%
  • 2022: Up 133%
Kanghong Pharmaceutical Doctoral Hiring by Year: 2026 — 56 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Chengdu Kanghong Pharmaceutical Group Joint-stock Co., Ltd. growing? Kanghong PharmaceuticalDoctorate recruitment over the years: 2026: 88 openings (up 175%), 2025: 32 openings (up 191%), 2024: 11 openings (down 15%), 2023: 13 openings (down 7%), 2022: 14 openings (up 133%), 2021: 6 openings. Kanghong Pharmaceutical doctorate talent ranking in Chengdu: #1, Kanghong Pharmaceutical doctorate salary mostly around 20-50K.

Kanghong Pharmaceutical R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Chengdu Kanghong Pharmaceutical Group Joint-stock Co., Ltd.? Based on an analysis of Kanghong Pharmaceutical's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 55.4%, "Computer/Network/Technology": 29.7%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 19.8%, "Other (R&D and Technical)": 5%, "Scientific Research": 3.9%, "Mechanical/Instrumentation": 1.3%. For reference only.

Kanghong Pharmaceutical — What Are the Salaries Like? (1977 records)

Manage
Kanghong Pharmaceutical Salary Overview
salary range: 6K - 50K, 47.5% of roles pay ¥10-20K
Note: salary statistics are based on 1977 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Chengdu Kanghong Pharmaceutical Group Joint-stock Co., Ltd.?Kanghong Pharmaceutical47.5% of positions earn 10-20K, Fresh graduate salary: ¥8.5K。Chengdu salary ranking top 15,医疗卫生/美容保健类 average salary ¥19.1K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Kanghong Pharmaceutical

(More)
Are salaries high at Chengdu Kanghong Pharmaceutical Group Joint-stock Co., Ltd.? We provide: Information, 临床, RA, Regional Manager, Researcher, Provincial Director, Medical Manager, Medical Director, Process Technician, Operations, 检验, Quality, Vice President, Intern, Marketing, Business Manager, Project Manager, QA, Product Manager, Distribution Specialist. Click to view detailed salary analysis by job.

Kanghong Pharmaceutical — Fortune 500? (More)

Yes, ranked in 中国新经济500强:

  • NO.280 2025中国新经济500强 >
  • NO.309 2024中国新经济500强 >
  • NO.392 2023中国新经济500强 >

Yes, ranked in 中国企业慈善公益500强:

  • NO.338 2022中国企业慈善公益500强 >
  • NO.122 2021中国企业慈善公益500强 >

Job Category

  • 医疗卫生/美容保健类
    54.2% of total 54.2%
  • 销售类
    41% of total 41%
  • 计算机/网络/技术类
    28.4% of total 28.4%
  • 生物/制药/化工/环保类
    20.7% of total 20.7%

Education

  • 本科
    41.8% of total 41.8%
  • 大专
    34.9% of total 34.9%
  • 硕士
    13.7% of total 13.7%
  • 博士
    4.2% of total 4.2%

Experience

  • 1-3年
    39.3% of total 39.3%
  • 3-5年
    20.7% of total 20.7%
  • 不限
    20.1% of total 20.1%
  • 应届生
    10.6% of total 10.6%
View Detailed Analysis

What does Chengdu Kanghong Pharmaceutical Group Joint-stock Co., Ltd. require? Who is Kanghong Pharmaceutical hiring? Kanghong Pharmaceutical recruitment: 医疗卫生/美容保健类占比最多占54.2%,其次是销售类占41%. What education can get in at Kanghong Pharmaceutical? 本科占比最多占41.8%,其次是大专占34.9%. High education required at Kanghong Pharmaceutical? 硕士占13.7%,博士占4.2%. Work experience required at Kanghong Pharmaceutical? 1-3年占比最多占39.3%,其次是3-5年占20.7%. Where are the job locations at Kanghong Pharmaceutical? 成都占比最多占44.5%,其次是北京占7.1%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 91,986.9004万(元)
Legal Representative: 柯尊洪
Date Established:
Credit Code: 91510100633116839D
Registered Address: 四川省成都市金牛区蜀西路108号

Partners & Suppliers

四川聚创医药有限公司作为康弘药业经销商,采购其眼科及中枢神经类药品 Source
合作客户 药品供应
供应康柏西普(朗沐)眼用注射液 Source
合作客户 眼科药品
重庆医药集团四川医药有限公司与康弘药业签订药品购销协议,采购其眼科、中枢神经系统等药物。 Source
合作客户 药品采购
在阿里健康平台开设康弘旗舰店,合作开展药品在线销售及互联网医疗服务。 Source
合作客户 医药电商
希迪制药向康弘药业供应眼科药物中间体 Source
供应商 原料药供应

People who follow Kanghong Pharmaceutical also follow

Kanghong Pharmaceutical Competitors (Similar Companies)

“Professional manufacturer and operator of large-volume parenteral solu”
医药 生物医药 单克隆抗体药物 高通量筛选
“Let everyone have trust and expectation in Baili because of health!”
V
“Health for all, vitality for life!”
“Research, development, and production of anti-tumor and surgical medic”
“For a Better Life”
“Adhering to the pursuit of high quality”
“A comprehensive pharmaceutical enterprise integrating drug R&D, produc”
“A renowned enterprise in China's liver disease and anti-tumor fields”
制药/药业 药物研发 生物制药 医药
医药流通 生产 医药配送 销售
洁净技术 房屋建筑工程 机电工程 消防设施工程
医药 生物制品 化学制药 药物研发
“To become a first-class enterprise in the global diagnostics industry”
“Accelerating global biologic drug R&D processes, reducing R&D costs, a”

Discover Great Companies, Discover Great Clients

成都公司名录 成都“Jinniu District”公司名录 成都“制药/药业”公司名录 成都“医药”公司名录 成都“抗肿瘤药”公司名录 成都“心血管药”公司名录 成都“生物制品”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates